Soleno Therapeutics (SLNO) Capital Expenditures (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Capital Expenditures of $4000.0 for Q1 2026, down 93.1% quarter-over-quarter from $58000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Capital Expenditures (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Capital Expenditures for 12 consecutive years, with $4000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $4000.0; the TTM figure through Mar 2026 stood at $77000.0 (down 62.8% YoY), while the FY2025 annual figure was $73000.0, down 66.51% from the prior year.
- Capital Expenditures fell to $4000.0 in Q1 2026 per SLNO's latest filing, from $58000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $191000.0 in Q3 2024 and bottomed at -$7000.0 in Q4 2022.
- Historically, Capital Expenditures has averaged $32000.0 across 4 years, with a median of $8000.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures slumped 153.85% — and 2025, when it surged 625.0%.
- Soleno Therapeutics' Capital Expenditures stood at -$7000.0 in 2022, then soared by 214.29% to $8000.0 in 2024, then soared by 625.0% to $58000.0 in 2025, then sank by 93.1% to $4000.0 in 2026.
- Business Quant data shows SLNO's Capital Expenditures at $4000.0 in Q1 2026, $58000.0 in Q4 2025, and $1000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 191,000.00 |
| Sep 30, 2024 | 191,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2022 | -7,000.00 |
| Dec 31, 2022 | -7,000.00 |
| Dec 31, 2021 | 13,000.00 |
| Dec 31, 2021 | 13,000.00 |